Skip to main content

Table 7 Spearman correlation coefficients between changes in PRO scores and in UC-DAI total scores from baseline to Week 8 in the acute phase

From: Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study

 

N

ρ (95% CI)

SF-12v2

 Physical functioning

532

−0.32 (−0.39, −0.24)

 Role physical

527

−0.44 (− 0.51, − 0.37)

 Bodily pain

522

− 0.41 (− 0.48, − 0.34)

 General health

532

− 0.40 (− 0.47, − 0.33)

 Vitality

523

− 0.35 (− 0.42, − 0.27)

 Social functioning

532

− 0.43 (− 0.50, − 0.36)

 Role emotional

529

− 0.40 (− 0.47, − 0.33)

 Mental health

532

−0.31 (− 0.38, − 0.23)

 PCS

531

− 0.43 (− 0.50, − 0.36)

 MCS

531

−0.37 (− 0.44, − 0.29)

SIBDQ

 Bowel symptoms

442

−0.52 (− 0.58, − 0.45)

 Systemic symptoms

458

−0.33 (− 0.41, − 0.25)

 Emotional function

453

−0.47 (− 0.54, − 0.39)

 Social function

461

−0.52 (− 0.58, − 0.45)

 Total score

430

−0.53 (− 0.59, − 0.46)

WPAI:UC

 Absenteeism

223

0.31 (0.19, 0.42)

 Presenteeism

229

0.36 (0.24, 0.47)

 Overall work impairment

218

0.44 (0.33, 0.54)

 Activity impairment

418

0.48 (0.40, 0.55)

  1. CI confidence interval, MCS mental component summary, PCS physical component summary, PRO patient-reported outcomes, SF-12v2 SF-12v2 Health Survey, SIBDQ Short Inflammatory Bowel Disease Questionnaire, UC-DAI Ulcerative Colitis Disease Activity Index, WPAI:UC Work Productivity and Activity Impairment questionnaire for ulcerative colitis
  2. Week 8 includes early withdrawal visits during the acute phase
  3. All correlation coefficients are statistically different from 0 (all P < 0.001)